An anti-Ang2 antibody or an antigen-binding fragment thereof that specifically binds to an angiogenesis-inducing factor Angiopoietin-2 (Ang2) and complexes with a Tie2 receptor and Ang2, and related methods and compositions.

To prompt input and provide feedback on input to a user with an interface, inputs and graphical cursors associated with those inputs are defined. Each input may have several forms such as base, hover, engaged, completed, and error. User input is anticipated. The base form of the anticipated input cursor is displayed to prompt the user for the anticipated input. If user hover is detected that matches anticipated input, the hover form is displayed to confirm the match to the user. If user input is detected that matches anticipated input, the engaged form is displayed as confirmation. If user input is completed that matches anticipated input, the completed form is displayed as confirmation. If user hover or input does not match anticipated input, the error form is displayed to indicate mismatch. Not all cursors must have all forms, and some cursors may have multiples of some forms.

An anti-c-Met/anti-Ang2 bispecific antibody including (a) an anti-c-Met antibody or antigen-binding fragment thereof and (b) an anti-Ang2 antibody or antigen-binding fragment thereof, a pharmaceutical composition including the anti-c-Met/anti-Ang2 bispecific antibody, and a method using the anti-c-Met/anti-Ang2 bispecific antibody.

An anti-c-Met/anti-Ang2 bispecific antibody including (a) an anti-c-Met antibody or antigen-binding fragment thereof and (b) an anti-Ang2 antibody or antigen-binding fragment thereof, a pharmaceutical composition including the anti-c-Met/anti-Ang2 bispecific antibody, and a method using the anti-c-Met/anti-Ang2 bispecific antibody.

Methods, compositions, and systems for treating ischemia-associated and other ocular conditions using cartilage oligo matrix protein-Angiopoietin 1 (COMP-Ang1) are disclosed and described.

Methods, compositions, and systems for treating ischemia-associated and other ocular conditions using cartilage oligo matrix protein-Angiopoietin 1 (COMP-Ang1) are disclosed and described.

The invention provides a method of treating a disorder characterized by elevated or dysregulated myostatin, disorders where the interaction between follistatin and angiogenin can be used to improve function in tissues, neurological diseases or disorders, spinal injuries or diseases, bone diseases or disorders, diseases involving glucose homeostasis, wound healing, neuroprotection, nervous system functional support or managing metabolic diseases, the method comprising administering an effective amount of angiogenin or an angiogenin agonist. Compositions and neutraceuticals comprising angiogenin are also provided.

The invention provides a method of treating a disorder characterized by elevated or dysregulated myostatin, disorders where the interaction between follistatin and angiogenin can be used to improve function in tissues, neurological diseases or disorders, spinal injuries or diseases, bone diseases or disorders, diseases involving glucose homeostasis, wound healing, neuroprotection, nervous system functional support or managing metabolic diseases, the method comprising administering an effective amount of angiogenin or an angiogenin agonist. Compositions and neutraceuticals comprising angiogenin are also provided.

The invention provides pluripotent stem cells and methods for making and using pluripotent stem cells. Pluripotent stem cells, among other things, can differentiate into various cell lineages in vitro, ex vivo and in vivo. Pluripotent stem cells, among other things, can also be used to produce conditioned medium.

The present invention provides for methods and compositions for treating or preventing arthritis and joint injury.